Radiation therapy remains one of the most widely used and effective pillars of cancer care. Over the past decades, advances in imaging, treatment planning, and beam delivery have enabled increasingly conformal radiation, allowing clinicians to target tumors with greater precision and spare surrounding organs. Yet a central challenge persists: tumor control is often dose dependent, and the ability to escalate dose is limited by the risk of severe, sometimes irreversible, toxicity in healthy tissues.
FLASH radiotherapy (FLASH-RT) is an emerging approach that could fundamentally shift this balance. Defined by the ultrafast delivery of radiation at ultra-high dose rates, FLASH-RT delivers therapeutic doses in fractions of a second, at dose rates several orders of magnitude higher than conventional radiotherapy. Early evidence suggests that this dramatic change in delivery time may reduce radiation-induced injury in normal tissues without compromising anti-cancer effects, opening the possibility of safer dose escalation and improved outcomes for selected tumors.
What Is FLASH Radiotherapy?
FLASH radiotherapy refers to the delivery of radiation at dose rates typically exceeding 40 Gy per second, in contrast to conventional radiotherapy, which is commonly delivered at approximately 0.5 to 5 Gy per minute. This difference is not merely technical; it represents a distinct time dose structure that may change how tissues respond to radiation. Rather than spreading dose delivery over minutes, FLASH Radiotherapy compresses treatment into milliseconds, creating an ultra-brief exposure window that appears to alter radiobiological responses in ways that favor normal tissue protection.
This concept has generated significant interest because it proposes a rare combination in oncology: maintaining tumor control while reducing side effects. If these effects are confirmed clinically, FLASH-RT could become a major addition to radiotherapy, and potentially a preferred approach for certain indications.
Why Speed May Matter: The Proposed Biological Advantage
Preclinical research has repeatedly shown that FLASH-RT can reduce damage to healthy tissues compared with conventional dose-rate radiotherapy. The most widely discussed explanation for this protective effect involves oxygen dynamics. Because radiation-induced tissue damage is strongly influenced by oxygen, the ultrafast delivery of radiation may rapidly deplete oxygen in normal tissues, causing a transient hypoxic state that reduces free-radical mediated injury. Normal tissues are generally well-oxygenated and capable of maintaining oxygen balance, while tumors often contain regions of chronic hypoxia and disordered vasculature, which may limit the protective benefit in malignant tissue.
Animal studies suggest that these effects may translate into reduced toxicity in organs that typically constrain radiation dosing, including the brain, lung, skin, and gastrointestinal tract. At the same time, the anti-tumor effect appears broadly preserved in many models, which is central to the promise of an improved therapeutic index. However, the biological picture is not fully settled. Immune effects, DNA damage response pathways, inflammatory signaling, and differences among tumor microenvironments may all contribute, and these mechanisms remain active areas of investigation.
How FLASH Is Delivered: The Physics Behind a 0.1-Second Treatment
Modern linear accelerators deliver radiation in pulses rather than as a perfectly continuous stream. In conventional radiotherapy, pulses are delivered at set frequencies and the overall treatment time extends over minutes, producing an average dose rate that is relatively low even if the instantaneous dose rate within each pulse is higher. In FLASH-RT, the overall dose is delivered in far fewer pulses over a dramatically shorter time, requiring much greater energy transfer per pulse and substantially higher average dose rates.
This change has real clinical implications. Delivering 8 Gy in conventional settings may take minutes, whereas in FLASH-RT it can be delivered in around 0.2 seconds. The difference in dose per pulse and energy load is enormous, and that creates a technological challenge: the beam must be stable, predictable, and measurable at ultra-high dose rates, while maintaining accuracy that is acceptable for clinical practice.
Dosimetry at Ultra-High Dose Rates: A Critical Bottleneck
Accurate dosimetry is essential in radiotherapy, but FLASH conditions push measurement systems to their limits. The pulsed, high-intensity delivery can produce saturation, recombination effects, and nonlinear responses in detectors that perform reliably under conventional dose rates. Real-time monitoring becomes particularly challenging when treatment is completed in milliseconds, leaving minimal opportunity for correction if dose deviates from the prescribed value.
To support FLASH Radiotherapy, dosimetric systems must be able to characterize the delivered dose per pulse, dose-rate within each pulse, pulse duration, pulse interval, and total irradiation time with high reliability. Emerging approaches include advanced luminescent detectors, scintillation-based systems, and Cherenkov detectors, which offer high time resolution and relative dose-rate independence. Even so, the field is still developing the robust, standardized solutions needed for widespread clinical deployment.
AI in Radiotherapy Planning and Workflow Optimization 2026
What We Know Clinically: Early Experience, Limited Data
Despite the growing volume of preclinical evidence, clinical experience with FLASH Radiotherapy remains very limited. A landmark human report described the treatment of a patient with cutaneous T-cell lymphoma using electron FLASH-RT, achieving a complete and durable response with minimal toxicity. This case demonstrated feasibility and safety in a real-world setting, but it does not yet establish effectiveness across tumor types, anatomical sites, or patient populations. Meaningful clinical adoption will depend on carefully designed trials and the availability of machines capable of delivering FLASH beams reliably and safely.
The Depth Problem: Why Electrons Alone Are Not Enough
Most FLASH preclinical work has been performed with electron beams. The limitation is that electrons produced by conventional medical linear accelerators have restricted penetration, making them suitable primarily for superficial lesions or tumors located within a few centimeters of the body surface. Many of the cancers with the greatest need for toxicity reduction, such as tumors near the heart, lungs, or deep abdominal organs, require dose delivery at depths of 10 to 20 centimeters.
For FLASH Radiotherapy to reach its full clinical potential, ultra-high dose-rate delivery must be achieved with radiation types that can treat deep-seated tumors. This includes photon-based FLASH, proton-based FLASH, and potentially very high energy electrons. Each approach brings major engineering and physics challenges.
Photon, Proton, and Very High Energy Electron FLASH: The Next Frontier
Photon-based FLASH is appealing because photon beams are already the backbone of conventional radiotherapy and can reach deep targets effectively. The challenge lies in generating ultra-high dose-rate photons, because converting electron energy into photons is inefficient, and much of the energy is lost as heat. Achieving FLASH photon beams may require sources capable of producing dramatically more electrons than current machines can generate, along with new solutions for beam conversion, cooling, and stability.
Proton-based FLASH is another highly promising route because protons can penetrate to clinically relevant depths and offer favorable dose distributions. Early studies suggest that ultra-high dose-rate proton delivery may spare normal tissue, possibly involving immune-mediated mechanisms. However, key questions remain about how increasing linear energy transfer near the Bragg peak interacts with the FLASH effect and how tissue oxygenation influences outcomes under proton irradiation.
Very high energy electrons could also provide deeper penetration than standard medical electrons, but building compact, clinically practical accelerators that generate such beams remains a significant technical hurdle.
Radiotherapy Journey on OncoDaily in 2025
Where FLASH-RT Could Fit in Oncology
If the FLASH effect is confirmed in clinical trials and supported by reliable technology, FLASH-RT could be most impactful in two broad scenarios. The first involves radioresistant tumors, where effective control may require dose escalation that is currently limited by toxicity. The second involves tumors close to critical organs, where conventional treatment is constrained by the narrow margin between tumor control and organ injury. In both cases, normal tissue sparing could increase the feasibility of curative treatment or reduce long-term side effects, improving both survival and quality of life.
Another potential advantage arises from treatment speed. Ultrafast delivery could reduce the impact of intratreatment motion from breathing or organ movement, potentially improving target accuracy and simplifying motion management. For deep tumors, however, this benefit will still require sophisticated image guidance and precise planning.
Written by Nare Hovhannisyan, MD